NEW YORK – Doctors Without Borders/Médecins Sans Frontières (MSF) on Thursday sent an open letter to Danaher and its subsidiary Cepheid calling for a lower price for Cepheid's Xpert MTB/RIF Ultra tuberculosis test.

纽约——无国界医生组织/无国界医生组织（MSF）周四向Danaher及其子公司Cepheid发出了一封公开信，呼吁降低Cepheid的Xpert MTB/RIF Ultra tuberculosis测试的价格。

After a campaign from the organization to convince the companies to lower the price of the test to $5.00 to increase access to the test, Danaher last year announced that it would provide the test at cost for $7.97 to the Global Fund to Fight AIDS, TB, and Malaria and to less-developed countries eligible for Cepheid's Global Access Program..

在该组织说服这些公司将测试价格降至5美元以增加测试机会的运动之后，Danaher去年宣布，它将以7.97美元的价格向全球抗击艾滋病、结核病和疟疾基金以及有资格参加造父变星全球通入计划的欠发达国家提供测试。。

Danaher also agreed to validate the actual cost of the test with an internationally accredited third-party assessment and adjust its pricing if necessary, but the MSF said in its letter Thursday that Danaher has 'made no headway on the audit you committed to, compounded by the failure to reduce the price of other priority test cartridges, such as that for extensively drug-resistant (XDR) TB, HIV, hepatitis, Ebola, and sexually transmitted infections, for which expansion of access continues to be urgent.'.

Danaher还同意通过国际认可的第三方评估来验证测试的实际成本，并在必要时调整其价格，但无国界医生组织（MSF）在周四的信中表示，Danaher“在您承诺的审计方面没有取得任何进展，加上未能降低其他优先测试药盒的价格，例如广泛耐药（XDR）结核病、艾滋病毒、肝炎、埃博拉病毒和性传播感染的测试药盒，因此扩大获取渠道仍然是当务之急。”。

The letter also noted that the MSF Access Campaign's efforts to discuss GeneXpert's affordability barriers and the methodology for the audit have not been successful due to a lack of response from Danaher and Cepheid regarding multiple meeting offers. In addition, letters of appeal from the health ministries of seven countries requesting a reduction in the price of GeneXpert tests remain unanswered, MSF said..

信中还指出，由于Danaher和Cepheid对多次会议提议缺乏回应，无国界医生组织访问运动讨论GeneXpert的负担能力障碍和审计方法的努力并未取得成功。此外，无国界医生组织表示，七个国家卫生部要求降低GeneXpert检测价格的呼吁信仍未得到回应。。

The letter provides the signatures of more than 200,000 people who have endorsed the campaign's 'Time for $5' petition, including healthcare workers, policy advocates, researchers, scientists, and company shareholders. MSF requested a written response by Oct. 25, 2024, that provides concrete plans to meet their demands..

这封信提供了20多万人的签名，他们支持该运动的“5美元时间”请愿书，包括医护人员、政策倡导者、研究人员、科学家和公司股东。无国界医生组织要求在2024年10月25日前作出书面答复，提供满足其要求的具体计划。。

In a separate statement, Mihir Mankad, director of global health advocacy and policy at MSF USA, said, 'Our research shows that Danaher and Cepheid could charge $5 per test and still make a reasonable profit, so it's inexcusable that they are still charging more than triple that price in even the poorest countries for most of the tests they produce.'.

无国界医生组织（MSF USA）全球健康倡导和政策主管米希尔·曼卡德（MihirMankad）在另一份声明中表示，“我们的研究表明，达纳赫（Danaher）和造父变星（Cepheid）每项检测收费5美元，但仍能获得合理的利润，因此，即便是在最贫穷的国家，他们生产的大多数检测产品的价格仍然是该价格的三倍以上，这是不可原谅的。”。

Cepheid's Xpert MTB/RIF Ultra is a real-time PCR assay that runs on the company's GeneXpert family of systems and simultaneously detects Mycobacterium tuberculosis and rifampicin resistance from patient samples.

造父变星的Xpert MTB/RIF Ultra是一种实时PCR检测方法，可在该公司的GeneXpert系列系统上运行，同时检测患者样本中的结核分枝杆菌和利福平耐药性。